FoundationOne CDx (F1CDx)
FDA premarket approval P170019/S029 · decided 2022-02-18
Approval details
- PMA number
- P170019
- Supplement
- S029
- Supplement type
- Panel Track
- Supplement reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Trade name
- FoundationOne CDx (F1CDx)
- Generic name
- Next generation sequencing oncology panel, somatic or germline variant detection system
- Applicant
- Foundation Medicine, Inc.
- Date received
- 2021-04-19
- Decision date
- 2022-02-18
- Days to decision
- 305 days
- Decision code
- APPR
- Product code
- PQP
- Advisory committee
- Pathology
- Expedited review
- No
- Location
- Boston, MA
- Statement
- Approval order to expand the intended use of FoundationOne®CDx (F1CDx) to include a companion diagnostic (CDx) indication for the detection of microsatellite instability High (MSI-H) status in patients with solid tumors who may benefit from treatment with KEYTRUDA® (pembrolizumab).
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.